Exclusive: Potential coronavirus treatment touted by Trump already in shortage – pharmacists

By Michael Erman

NEW YORK (Reuters) – Supply of a malaria treatment that has been tried with some success against the new coronavirus is in short supply as demand surges amid the fast-spreading outbreak, according to independent pharmacies and the American Society of Health-System Pharmacists (ASHP).

The ASHP, which maintains a list of drugs in shortage independent of the U.S. Food and Drug Administration’s list, plans to add the generic malaria drug hydroxychloroquine to its list of shortages later on Thursday, according to Erin Fox, senior director of drug information at University of Utah Health, who maintains the shortages list for the ASHP.

The FDA could not be immediately reached for comment, but hydroxychloroquine is not currently on its list of drugs in shortage.

U.S. President Donald Trump on Thursday called on U.S. health regulators to expedite potential therapies aimed at treating COVID-19 for which there is no approved treatments or vaccines.

He said the government was looking at hydroxychloroquine and Gilead Sciences Inc ‘s (O:) experimental antiviral drug Remdesivir, which is undergoing clinical trials for the respiratory illness.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.